These characteristics make STING agonists an ideal candidate for combination with ICI (such as anti-PD-1/PD-L1, CTLA-4 antibodies) [103,104], which only work in a fraction of patients with good anti-tumor effects. Here, CTLA4 is linked to neoplasm.